My Bibliography

select

Ozcan U, Yilmaz E, Ozcan L, Furuhashi M, Vaillancourt E, Smith RO, Görgün CZ, Hotamisligil GS. Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes. Science. 2006 Aug 25;313(5790):1137-40. doi: 10.1126/science.1128294. PubMed PMID: 16931765; PubMed Central PMCID: PMC4741373.

select

Ozcan U, Ozcan L, Yilmaz E, Düvel K, Sahin M, Manning BD, Hotamisligil GS. Loss of the tuberous sclerosis complex tumor suppressors triggers the unfolded protein response to regulate insulin signaling and apoptosis. Mol Cell. 2008 Mar 14;29(5):541-51. doi: 10.1016/j.molcel.2007.12.023. PubMed PMID: 18342602; PubMed Central PMCID: PMC2361721.

select

Ozcan L, Ergin AS, Lu A, Chung J, Sarkar S, Nie D, Myers MG Jr, Ozcan U. Endoplasmic reticulum stress plays a central role in development of leptin resistance. Cell Metab. 2009 Jan 7;9(1):35-51. doi: 10.1016/j.cmet.2008.12.004. PubMed PMID: 19117545; NIHMSID:NIHMS278674.

select

Timmins JM, Ozcan L, Seimon TA, Li G, Malagelada C, Backs J, Backs T, Bassel-Duby R, Olson EN, Anderson ME, Tabas I. Calcium/calmodulin-dependent protein kinase II links ER stress with Fas and mitochondrial apoptosis pathways. J Clin Invest. 2009 Oct;119(10):2925-41. doi: 10.1172/JCI38857. Epub 2009 Sep 8. PubMed PMID: 19741297; PubMed Central PMCID: PMC2752072.

select

Ozcan L, Tabas I. Pivotal role of calcium/calmodulin-dependent protein kinase II in ER stress-induced apoptosis. Cell Cycle. 2010 Jan 15;9(2):223-4. doi: 10.4161/cc.9.2.10596. Epub 2010 Jan 10. PubMed PMID: 20023415; PubMed Central PMCID: PMC2846633.

select

Li G, Scull C, Ozcan L, Tabas I. NADPH oxidase links endoplasmic reticulum stress, oxidative stress, and PKR activation to induce apoptosis. J Cell Biol. 2010 Dec 13;191(6):1113-25. doi: 10.1083/jcb.201006121. Epub 2010 Dec 6. PubMed PMID: 21135141; PubMed Central PMCID: PMC3002036.

select

Ozcan L, Tabas I. Role of endoplasmic reticulum stress in metabolic disease and other disorders. Annu Rev Med. 2012;63:317-28. doi: 10.1146/annurev-med-043010-144749. Review. PubMed PMID: 22248326; PubMed Central PMCID: PMC3290993.

select

Ozcan L, Wong CC, Li G, Xu T, Pajvani U, Park SK, Wronska A, Chen BX, Marks AR, Fukamizu A, Backs J, Singer HA, Yates JR 3rd, Accili D, Tabas I. Calcium signaling through CaMKII regulates hepatic glucose production in fasting and obesity. Cell Metab. 2012 May 2;15(5):739-51. doi: 10.1016/j.cmet.2012.03.002. Epub 2012 Apr 12. PubMed PMID: 22503562; PubMed Central PMCID: PMC3348356.

select

Ozcan L. Endoplasmic reticulum stress in cardiometabolic disorders. Curr Atheroscler Rep. 2012 Oct;14(5):469-75. doi: 10.1007/s11883-012-0270-z. Review. PubMed PMID: 22847769.

select

Ozcan L, Cristina de Souza J, Harari AA, Backs J, Olson EN, Tabas I. Activation of calcium/calmodulin-dependent protein kinase II in obesity mediates suppression of hepatic insulin signaling. Cell Metab. 2013 Dec 3;18(6):803-15. doi: 10.1016/j.cmet.2013.10.011. Epub 2013 Nov 21. PubMed PMID: 24268736; PubMed Central PMCID: PMC3863383.

select

Ozcan L, Tabas I. CaMKII in cardiometabolic disease. Aging (Albany NY). 2014 Jun;6(6):430-1. doi: 10.18632/aging.100675. PubMed PMID: 25011473; PubMed Central PMCID: PMC4100805.

select

Fredman G, Ozcan L, Tabas I. Common therapeutic targets in cardiometabolic disease. Sci Transl Med. 2014 Jun 4;6(239):239ps5. doi: 10.1126/scitranslmed.3008908. Review. PubMed PMID: 24898746; PubMed Central PMCID: PMC4176709.

select

Fredman G, Ozcan L, Spolitu S, Hellmann J, Spite M, Backs J, Tabas I. Resolvin D1 limits 5-lipoxygenase nuclear localization and leukotriene B4 synthesis by inhibiting a calcium-activated kinase pathway. Proc Natl Acad Sci U S A. 2014 Oct 7;111(40):14530-5. doi: 10.1073/pnas.1410851111. Epub 2014 Sep 22. PubMed PMID: 25246560; PubMed Central PMCID: PMC4210018.

select

Subramanian M, Ozcan L, Ghorpade DS, Ferrante AW Jr, Tabas I. Suppression of Adaptive Immune Cell Activation Does Not Alter Innate Immune Adipose Inflammation or Insulin Resistance in Obesity. PLoS One. 2015;10(8):e0135842. doi: 10.1371/journal.pone.0135842. eCollection 2015. PubMed PMID: 26317499; PubMed Central PMCID: PMC4552860.

select

Ozcan L, Xu X, Deng SX, Ghorpade DS, Thomas T, Cremers S, Hubbard B, Serrano-Wu MH, Gaestel M, Landry DW, Tabas I. Treatment of Obese Insulin-Resistant Mice With an Allosteric MAPKAPK2/3 Inhibitor Lowers Blood Glucose and Improves Insulin Sensitivity. Diabetes. 2015 Oct;64(10):3396-405. doi: 10.2337/db14-1945. Epub 2015 Jun 11. PubMed PMID: 26068544; PubMed Central PMCID: PMC4587644.

select

Ozcan L, Ghorpade DS, Zheng Z, de Souza JC, Chen K, Bessler M, Bagloo M, Schrope B, Pestell R, Tabas I. Hepatocyte DACH1 Is Increased in Obesity via Nuclear Exclusion of HDAC4 and Promotes Hepatic Insulin Resistance. Cell Rep. 2016 Jun 7;15(10):2214-2225. doi: 10.1016/j.celrep.2016.05.006. Epub 2016 May 26. PubMed PMID: 27239042; PubMed Central PMCID: PMC5068925.

select

Doran AC, Ozcan L, Cai B, Zheng Z, Fredman G, Rymond CC, Dorweiler B, Sluimer JC, Hsieh J, Kuriakose G, Tall AR, Tabas I. CAMKIIγ suppresses an efferocytosis pathway in macrophages and promotes atherosclerotic plaque necrosis. J Clin Invest. 2017 Nov 1;127(11):4075-4089. doi: 10.1172/JCI94735. Epub 2017 Oct 3. PubMed PMID: 28972541; PubMed Central PMCID: PMC5663361.

select

Kim K, Ryu D, Dongiovanni P, Ozcan L, Nayak S, Ueberheide B, Valenti L, Auwerx J, Pajvani UB. Degradation of PHLPP2 by KCTD17, via a Glucagon-Dependent Pathway, Promotes Hepatic Steatosis. Gastroenterology. 2017 Dec;153(6):1568-1580.e10. doi: 10.1053/j.gastro.2017.08.039. Epub 2017 Aug 30. PubMed PMID: 28859855; PubMed Central PMCID: PMC5705280.

select

Ghorpade DS, Ozcan L, Zheng Z, Nicoloro SM, Shen Y, Chen E, Blüher M, Czech MP, Tabas I. Hepatocyte-secreted DPP4 in obesity promotes adipose inflammation and insulin resistance. Nature. 2018 Mar 29;555(7698):673-677. doi: 10.1038/nature26138. Epub 2018 Mar 21. PubMed PMID: 29562231; PubMed Central PMCID: PMC6021131.

select

Karanth S, Adams JD, Serrano MLA, Quittner-Strom EB, Simcox J, Villanueva CJ, Ozcan L, Holland WL, Yost HJ, Vella A, Schlegel A. A Hepatocyte FOXN3-α Cell Glucagon Axis Regulates Fasting Glucose. Cell Rep. 2018 Jul 10;24(2):312-319. doi: 10.1016/j.celrep.2018.06.039. PubMed PMID: 29996093; PubMed Central PMCID: PMC6086569.

select

Ozcan L, Tabas I. A New Activator of Hepatocyte CaMKII in Fasting and Type 2 Diabetes. Diabetes. 2018 Sep;67(9):1742-1744. doi: 10.2337/dbi18-0026. PubMed PMID: 30135135; PubMed Central PMCID: PMC6905480.

select

Spolitu S, Okamoto H, Dai W, Zadroga JA, Wittchen ES, Gromada J, Ozcan L. Hepatic Glucagon Signaling Regulates PCSK9 and Low-Density Lipoprotein Cholesterol. Circ Res. 2019 Jan 4;124(1):38-51. doi: 10.1161/CIRCRESAHA.118.313648. PubMed PMID: 30582457; PubMed Central PMCID: PMC6457439.

select

Zheng Z, Nayak L, Wang W, Yurdagul A Jr, Wang X, Cai B, Lapping S, Ozcan L, Ramakrishnan R, Pestell RG, Jain MK, Tabas I. An ATF6-tPA pathway in hepatocytes contributes to systemic fibrinolysis and is repressed by DACH1. Blood. 2019 Feb 14;133(7):743-753. doi: 10.1182/blood-2018-07-864843. Epub 2018 Dec 1. PubMed PMID: 30504459; PubMed Central PMCID: PMC6376283.

select

Spolitu S, Dai W, Zadroga JA, Ozcan L. Proprotein convertase subtilisin/kexin type 9 and lipid metabolism. Curr Opin Lipidol. 2019 Jun;30(3):186-191. doi: 10.1097/MOL.0000000000000601. Review. PubMed PMID: 30925519; PubMed Central PMCID: PMC6824479.

select

Zheng Z, Nakamura K, Gershbaum S, Wang X, Thomas S, Bessler M, Schrope B, Krikhely A, Liu RM, Ozcan L, López JA, Tabas I. Interacting hepatic PAI-1/tPA gene regulatory pathways influence impaired fibrinolysis severity in obesity. J Clin Invest. 2020 Aug 3;130(8):4348-4359. doi: 10.1172/JCI135919. PubMed PMID: 32657780; PubMed Central PMCID: PMC7410057.

select

Ozcan L, Ghorpade DS, Tabas I. Targeting Soluble DPP-4 for Insulin Resistance: Origin Matters. J Clin Endocrinol Metab. 2021 Mar 8;106(3):e1460-e1462. doi: 10.1210/clinem/dgaa902. PubMed PMID: 33274386; PubMed Central PMCID: PMC7947836.

select

Ozcan L, Kasikara C, Yurdagul A Jr, Kuriakose G, Hubbard B, Serrano-Wu MH, Tabas I. Allosteric MAPKAPK2 inhibitors improve plaque stability in advanced atherosclerosis. PLoS One. 2021;16(5):e0246600. doi: 10.1371/journal.pone.0246600. eCollection 2021. PubMed PMID: 33983975; PubMed Central PMCID: PMC8118275.

select

Dai W, Choubey M, Patel S, Singer HA, Ozcan L. Adipocyte CAMK2 deficiency improves obesity-associated glucose intolerance. Mol Metab. 2021 Nov;53:101300. doi: 10.1016/j.molmet.2021.101300. Epub 2021 Jul 22. PubMed PMID: 34303021; PubMed Central PMCID: PMC8365526.

select

Wang Y, Spolitu S, Zadroga JA, Sarecha AK, Ozcan L. Hepatocyte Rap1a contributes to obesity- and statin-associated hyperglycemia. Cell Rep. 2022 Aug 23;40(8):111259. doi: 10.1016/j.celrep.2022.111259. PubMed PMID: 36001955; PubMed Central PMCID: PMC9446800.

select

Agarwal H, Tinsley B, Sarecha AK, Ozcan L. Rap1 in the Context of PCSK9, Atherosclerosis, and Diabetes. Curr Atheroscler Rep. 2023 Dec;25(12):931-937. doi: 10.1007/s11883-023-01162-7. Epub 2023 Nov 18. Review. PubMed PMID: 37979063.

select

Wang Y, Tinsley B, Spolitu S, Zadroga JA, Agarwal H, Sarecha AK, Ozcan L. Geranylgeranyl isoprenoids and hepatic Rap1a regulate basal and statin-induced expression of PCSK9. J Lipid Res. 2024 Mar;65(3):100515. doi: 10.1016/j.jlr.2024.100515. Epub 2024 Feb 2. PubMed PMID: 38309417; PubMed Central PMCID: PMC10910342.

select

Agarwal H, Wang Y, Tinsley B, Wang X, Ozcan L. RAP1A suppresses hepatic steatosis by regulating amino acid-mediated mTORC1 activation. JHEP Rep. 2025 Apr;7(4):101303. doi: 10.1016/j.jhepr.2024.101303. eCollection 2025 Apr. PubMed PMID: 40124164; PubMed Central PMCID: PMC11929108.